Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.00.
A number of research firms recently commented on NVAX. TD Cowen upgraded Novavax to a “hold” rating in a report on Thursday, February 27th. Citigroup began coverage on Novavax in a report on Tuesday. They issued a “sell” rating and a $6.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a report on Friday, May 9th. B. Riley reiterated a “buy” rating on shares of Novavax in a report on Monday, May 19th. Finally, BTIG Research assumed coverage on Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective on the stock.
Get Our Latest Analysis on Novavax
Institutional Inflows and Outflows
Novavax Stock Performance
NVAX opened at $6.30 on Tuesday. Novavax has a one year low of $5.01 and a one year high of $17.81. The stock has a market capitalization of $1.02 billion, a PE ratio of 2.38, a P/E/G ratio of 0.07 and a beta of 2.80. The business’s 50 day moving average price is $6.73 and its 200 day moving average price is $7.65.
Novavax (NASDAQ:NVAX – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $2.22. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The firm had revenue of $666.66 million for the quarter, compared to analysts’ expectations of $204.08 million. During the same period in the prior year, the firm posted ($1.05) earnings per share. The firm’s quarterly revenue was up 610.3% on a year-over-year basis. As a group, equities research analysts forecast that Novavax will post -1.46 earnings per share for the current fiscal year.
Novavax Company Profile
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Stories
- Five stocks we like better than Novavax
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- How to find penny stocks to invest and trade
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- Financial Services Stocks Investing
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.